Theravance Antibiotic: Data Looks Good

The Science Business by Matthew Herper: "These data look pretty good. Televancin met its main goal of being statistically the same as vancomycin, the standard of care, in ventilator pneumonia. This is a pretty tough illness for a new drug. It's a good sign that the cure rate comes in numerically higher for televancin, although I'd quibble with the quote in the press release from Ralph Corey of Duke University. Saying a difference is clinically meaningful when it's not statistically significant is a little misleading. We don't know for sure the difference isn't due to the play of chance."